CDT Equity Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“May 21, 2026, CDT Equity Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Periodic Filing Requirement”) because the Company did not file its Quarterly Report on Form 10-Q for the three-month period ended March 31, 2026 (the “Form 10-Q”) in a timely manner, as required for continued listing on The Nasdaq Capital Market. The Notice has no immediate effect on the listing or trading of the Company’s”
Governance Changes
CDT Equity Inc.: filed amendment to effectuate 1-for-25 reverse stock split of common stock (effective 2026-03-26).
“On March 24, 2026, CDT Equity Inc. (the “Company”) filed a certificate of amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effectuate a 1-for-25 reverse stock split (the “Reverse Stock Split”) of the outstanding shares of the Company’s common stock”
Debt Financings
CDT Equity Inc. incurred convertible notes of $555,556 with an institutional investor at 10% maturing July 3, 2026.
“the Company issued a Senior Secured Convertible Promissory Note with a total principal amount of up to $555,556 (the “Note”). The Note bears interest at an annual rate of 10% and matures on July 3, 2026”
Material Agreements
CDT Equity Inc. entered into Securities Purchase Agreement with the Purchaser valued at total principal amount of up to $555,556 (effective 2026-03-03).
“the Company entered into a Securities Purchase Agreement (the "Note Purchase Agreement") with the Purchaser.”
Material Agreements
CDT Equity Inc. amended Purchase Agreement with an institutional investor (the "Purchaser") (effective 2026-03-03).
“the Company and Purchaser entered into an amendment to the Purchase Agreement (the "Amendment") in which the parties mutually agreed to lower the Floor Price (as defined in the Purchase Agreement) to $0.60.”
Material Agreements
CDT Equity Inc. amended Thesprogen Addendum with Thesprogen, PC valued at $245,000 (effective 2026-02-24).
“On February 24, 2026 (the “ Thesprogen Effective Date ”), the Company and Thesprogen entered into Addendum No. 1 to the Thesprogen Agreement (the “ Thesprogen Addendum ”) to extend the term of the Thesprogen Agreement an additional twelve months from its initial termination date, June 28, 2026, to June 28, 2027, unless terminated in accordance with its terms.”
Material Agreements
CDT Equity Inc. amended NJS Addendum with NJS Foresight Bio Advisory, LLC valued at $150,000 (effective 2026-02-23).
“On February 23, 2026 (the “ NJS Effective Date ”), the Company and NJS entered into Addendum No. 1 to the NJS Agreement (the “ NJS Addendum ”) to extend the term of the NJS Agreement an additional twelve months from its initial termination date, December 29, 2026, to December 29, 2027, unless terminated earlier in accordance with its terms.”
Material Agreements
CDT Equity Inc. entered into Securities Purchase Agreement with all of the stockholders of Sarborg Limited (effective 2026-02-19).
“On February 19, 2026, CDT Equity Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with all of the stockholders (collectively, the “ Investors ”) of Sarborg Limited, a Cayman Islands Company (“ Sarborg ”).”
Material Agreements
CDT Equity Inc. entered into Purchase Agreement with an institutional investor valued at up to $25 million (effective 2026-01-16).
“On January 16, 2026, CDT Equity Inc. (the “Company”), entered into a directed stock purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”) relating to an equity line of credit facility (the “ELOC”).”
Material Agreements
CDT Equity Inc. entered into NJS Agreement with NJS Foresight Bio-Advisory, LLC valued at one-time fixed retainer of $150,000 (effective 2025-12-29).
“On December 29, 2025 (the “Effective Date”) the Company and NJS Foresight Bio-Advisory, LLC (“NJS”) entered into a Consulting Agreement (the “NJS Agreement,” together with the Thesprogen Agreement, the “Agreements”)”
Material Agreements
CDT Equity Inc. entered into Thesprogen Agreement with Thesprogen, PC valued at $155,000 of consideration (effective 2025-12-28).
“On December 28, 2025, CDT Equity, Inc. (the “Company” or “CDT”) and Thesprogen, PC (“Thesprogen”) entered into a Consulting Agreement (the “Thesprogen Agreement”)”
Governance Changes
CDT Equity Inc.: Filed amendment to effect a 1-for-8 reverse stock split of common stock (effective 2025-10-10).
“On October 8, 2025, CDT Equity Inc. (the “Company”) filed a certificate of amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effectuate a 1-for-8 reverse stock split (the “Reverse Stock Split”) of the outstanding shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”).”
Auditor Changes
CDT Equity Inc. reported that prior financial statements should not be relied upon.
“On August 8, 2025, CDT Equity Inc. (the “Company”) determined, after discussions with its advisors and CBIZ CPAs P.C., the Company’s independent registered public accounting firm, that the Company’s previously issued unaudited financial statements, and notes related thereto, for the Subject Period (as defined below) should no longer be relied upon due to the restatement described below”
Governance Changes
CDT Equity Inc.: Amended and restated bylaws to reflect name change and update quorum description per a prior amendment (effective 2025-08-05).
“In connection with the Name Change, the Company also amended and restated its Amended and Restated Bylaws (as amended, the “ Second Amended and Restated Bylaws ”) on August 5, 2025 to reflect the Name Change.”
Governance Changes
CDT Equity Inc.: Amended certificate of incorporation to change company name from Conduit Pharmaceuticals Inc. to CDT Equity Inc (effective 2025-08-05).
“On August 5, 2025, the Company filed an amendment to its Second Amended and Restated Certificate of Incorporation (the “ Certificate of Incorporation ”), to effect a change of the Company’s name from “Conduit Pharmaceuticals Inc.” to “CDT Equity Inc.” (the “ Name Change ”), which became effective at 5 p.m. Eastern Time on August 5, 2025.”
Andrew Regan was appointed as Chief Executive Officer at CDT Equity Inc..
“On April 15, 2025, the Company appointed Andrew Regan as Chief Executive Officer, effective immediately.”
Simon Fry was appointed as director at CDT Equity Inc..
“the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.